Department of Public Health, Health Management and Policy, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Management Innovation Division, Mitsubishi Research Institute, Inc, 10-3, Nagatacho 2-Chome, Chiyoda-Ku, Tokyo, 100-8141, Japan.
Clin Exp Nephrol. 2022 Apr;26(4):360-367. doi: 10.1007/s10157-021-02163-z. Epub 2022 Jan 1.
The survival rate of chronic dialysis patients in Japan remains the highest worldwide, so there is value in presenting Japan's situation internationally. We examined whether aggregate figures on dialysis patients in the National Database of Health Insurance Claims and Special Health Checkups of Japan (NDB), which contains data on insured procedures of approximately 100 million Japanese residents, complement corresponding figures in the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR).
Subjects were patients with medical fee points for dialysis recorded in the NDB during 2014-2018. We analyzed annual numbers of dialysis cases, newly initiated dialysis cases- and deaths.
Compared with the JRDR, the NDB had about 6-7% fewer dialysis cases but a similar number of newly initiated dialysis cases. In the NDB, the number of deaths was about 6-10% lower, and the number of hemodialysis cases was lower, while that of peritoneal dialysis cases was higher. The cumulative survival rate at dialysis initiation was approximately 6 percentage points lower in the NDB than in the JRDR, indicating that some patients die at dialysis initiation. Cumulative survival rate by age group was roughly the same between the NDB and JRDR in both sexes.
The use of the NDB enabled us to aggregate data of dialysis patients. With the definition of dialysis patients used in this study, analyses of concomitant medications, comorbidities, surgeries, and therapies will become possible, which will be useful in many future studies.
日本慢性透析患者的存活率仍然是世界上最高的,因此在国际上介绍日本的情况具有价值。我们检查了日本国民健康保险索赔和特殊健康检查国家数据库(NDB)中透析患者的综合数据,该数据库包含了约 1 亿日本居民的保险程序数据,与日本透析治疗学会肾脏数据登记处(JRDR)的相应数据进行了比较。
研究对象为 NDB 中 2014-2018 年记录的透析医疗费用点患者。我们分析了每年的透析病例数、新开始透析病例数和死亡人数。
与 JRDR 相比,NDB 的透析病例数少了约 6-7%,但新开始透析病例数相似。在 NDB 中,死亡人数低了约 6-10%,血液透析病例数低了,而腹膜透析病例数高了。NDB 中透析开始时的累积生存率比 JRDR 低了约 6 个百分点,这表明有些患者在开始透析时死亡。男女两性 NDB 和 JRDR 的年龄组累积生存率大致相同。
使用 NDB 使我们能够汇总透析患者的数据。使用本研究中定义的透析患者,分析伴随药物、合并症、手术和治疗将成为可能,这将对许多未来的研究非常有用。